Paper I — 2025 August (Supplementary) (2010 Scheme) — Q18

Paper I

2025 August (Supplementary) (2010 Scheme) · 40 marks · 120 min

Question

COMT inhibitors.

Q180.3 marksShort Answers★✓

Answer

Entacapone, Tolcapone — inhibit catechol-O-methyltransferase, reducing peripheral (and, for tolcapone, central) breakdown of levodopa, prolonging its action and permitting a lower/less frequent dose; used as adjuncts to levodopa-carbidopa in Parkinson’s disease, particularly for “wearing-off” fluctuations.

Related Concepts

1. 1Antiparkinsonian Drugs

Other Years Asked

1. 1Drugs used to treat Parkinsonism. Describe the Mechanism of action and adverse effects of levodopa.2024 March (Supplementary) (2019 Scheme)Short Essay · 8 marks
2. 2Enumerate four groups of drugs used in the treatment of Parkinson’s disease. Describe the pharmacological actions and adverse effects of levodopa. What is the advantage of combining levodopa with the peripheral decarboxylase inhibitor. (2+3+1= 6)2015 September (Supplementary) (2010 Scheme)Essay · 6 marks
3. 3Pharmacotherapy of Parkinsonism.2022 July (Supplementary) (2019 Scheme)Short Answer · 4 marks
4. 4Levodopa2020 February (Supplementary) (2010 Scheme)Short Note · 3 marks
5. 5COMT inhibitors.2016 October (Supplementary) (2010 Scheme)Short Note · 3 marks
6. 6The medication preferred in the treatment of drug-induced parkinsonism is2025 March (Supplementary (SAY)) (2019 Scheme)MCQ · 1 mark
7. 7COMT inhibitors2018 July (Supplementary) (2010 Scheme)Short Answer · 1 mark
8. 8Idiopathic parkinsonism2014 March (2010 Scheme)Short Answer · 1 mark
9. 9Parkinson’s disease2016 February (2010 Scheme)Short Answer · 1 mark
10. 10Bromocriptine2019 July (Supplementary) (2010 Scheme)Short Answer · 1 mark
11. 11Peripheral decarboxylase inhibitor2022 May (Supplementary) (2010 Scheme)Short Answer · 0.3 marks
12. 12COMT inhibitor2019 February (2010 Scheme)Short Answer · 0.3 marks